Summary
• Protalix BioTherapeutics (PLX) shares dropped 6% to $1.68 in pre-market trading following a significant earnings miss.
• The company reported an EPS of $0.02914 versus an estimate of $0.06, leading to a quarterly performance decline of 7.6%.
• Analysts maintain a “Buy” rating with a revised price target of $12, while insider selling raises investor concerns about confidence.
Protalix BioTherapeutics, Inc. (PLX) is trading at $1.68 in pre-market, reflecting a drop of 6% compared to the last close of $1.78. This price movement is occurring without a clear catalyst for the decline.
Earnings Miss Weighs on Stock Performance
In its recent earnings report, Protalix reported third-quarter results on November 13, 2025, which featured a substantial earnings surprise as it posted an actual EPS of $0.02914 against an estimate of $0.06, constituting a surprise of approximately -51%. This considerable shortfall in earnings expectations potentially contributes to the downward pressure on the stock in today’s trading session.
The financial results also revealed a challenging landscape, with the company’s share price reflecting a quarterly performance decline of 7.6%. Notably, despite the earnings setback, the company has maintained an overall positive yearly performance of 71.1%, indicating some resilience amid the recent volatility.
Analyst Outlook and Insider Activity
Analyst sentiment remains cautiously optimistic. HC Wainwright & Co. recently maintained a “Buy” rating for Protalix, with a price target adjustment down to $12 from $15. Such adjustments highlight the ongoing complexities in the company’s financial outlook following the earnings miss.
Additionally, insider transaction data reveals that director Bar-Shalev Amos sold 168 shares at a price of $1.87 on November 18, amounting to a value of approximately $314.16. This activity may raise questions among investors regarding insider confidence as the stock navigates challenging market conditions.
Market and Technical Picture
The stock is currently experiencing a significant deviation from its technical indicators. The 20-day simple moving average (SMA) is down by 11.6%, indicating a bearish trend, while the Relative Strength Index (RSI) stands at 36.19, suggesting that the stock is nearing oversold territory. With an average 10-day volume of 473,904 and a 3-month average volume of 811,706, trading activity is relatively subdued, implying cautious investor sentiment.
In terms of volatility, the stock has seen a weekly volatility rate of 6.13%. Notably, Protalix’s price lies significantly below its 52-week high, underscoring the stock’s recent struggles.
Closing Thoughts
With no fresh catalyst in play, the move reflects routine market conditions as participants assess the implications of the recent earnings report and the broader outlook. Investors will be closely watching to see how the stock’s performance and volume dynamics develop in the upcoming session.